Home/Kinea Bio/Jeffrey Chamberlain, PhD
JC

Jeffrey Chamberlain, PhD

Co-founder, Chief Scientific Advisor

Kinea Bio

Therapeutic Areas

Kinea Bio Pipeline

DrugIndicationPhase
DMD Gene TherapyDuchenne Muscular DystrophyPre-clinical
Dysferlinopathy Gene TherapyDysferlinopathy (LGMD2B/LGMDR2)Pre-clinical
DM1 TherapyMyotonic Dystrophy Type 1Research